We are a biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology that function at the DNA level. Our Mission is to develop these small-molecule compounds to treat cancer and stroke in patients with the greatest unmet medical needs. We are committed to the highest standards of scientific excellence and integrity to accomplish these goals for patients, shareholders and society.
We value innovation, creativity and individual initiative.
We rely on collaborative relationships and collective success.
We strive for honesty and transparency in our conduct, every day.
We seek to recognize and acknowledge every individual’s success.
We are committed to performing reliably and delivering on our commitments in all our work.
We persevere in achieving excellence in all we do with widespread enthusiasm.
Rich Pharmaceuticals Explains How Targeted Immunotherapy Aids in the Treatment and Recovery of AML Patients
Rich Pharmaceuticals’ Study Drug RP-323 (TPA) is a Potential Therapeutic Agent for the Treatment of Hodgkin’s Lymphoma
Rich Pharmaceuticals’ Study Drug RP-323 (TPA) Elevates White Blood Cells (WBCs) Which Play a Vital Role Fighting Infections, and in Immunotherapy